MedPath

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Registration Number
NCT05342636
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with advanced esophageal cancer who have failed 1 prior line of therapy and have not been previously exposed to programmed cell death 1 protein (PD-1)/ programmed cell death ligand 1 (PD-L1) based treatment.

With protocol amendment 5 (effective: 17-November-2023), enrollment in study arms "Pembrolizumab plus MK-4830 plus Chemotherapy" and "Pembrolizumab plus MK-4830 plus lenvatinib" is discontinued.

Detailed Description

The master protocol is MK-3475-U06.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable ESCC
  • Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy.
  • Has an evaluable baseline tumor sample (newly obtained or archival) for analysis
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications
  • Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible
Exclusion Criteria
  • Direct invasion into adjacent organs such as the aorta or trachea
  • Has experienced weight loss >10% over approximately 2 months prior to first dose of study therapy
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • History of human immunodeficiency virus (HIV) infection
  • History of Hepatitis B or known active Hepatitis C virus infection
  • History of allogenic tissue/solid organ transplant
  • Clinically significant cardiovascular disease within 12 months from first dose of study intervention
  • Participants with known gastrointestinal (GI) malabsorption or any other condition that may affect the absorption of lenvatinib
  • Has risk for significant GI bleeding, such as:
  • Has had a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization
  • Has significant bleeding disorders, vasculitis, or has had a significant bleeding episode from the GI tract within 12 weeks prior to allocation/randomization

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pembrolizumab plus MK-4830 plus ChemotherapyMK-4830Participants will receive pembrolizumab intravenously plus MK-4830 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus MK-4830 plus lenvatinibPembrolizumabParticipants will receive pembrolizumab intravenously plus MK-4830 plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus chemotherapyIrinotecanParticipants will receive pembrolizumab intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Coformulation Favezelimab/Pembrolizumab plus ChemotherapyCoformulation favezelimab/pembrolizumabParticipants will receive coformulation of favezelimab/pembrolizumab administered intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus MK-4830 plus lenvatinibMK-4830Participants will receive pembrolizumab intravenously plus MK-4830 plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus chemotherapyPaclitaxelParticipants will receive pembrolizumab intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Coformulation Favezelimab/Pembrolizumab plus ChemotherapyIrinotecanParticipants will receive coformulation of favezelimab/pembrolizumab administered intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Coformulation Favezelimab/Pembrolizumab plus ChemotherapyPaclitaxelParticipants will receive coformulation of favezelimab/pembrolizumab administered intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus MK-4830 plus ChemotherapyIrinotecanParticipants will receive pembrolizumab intravenously plus MK-4830 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus MK-4830 plus ChemotherapyPaclitaxelParticipants will receive pembrolizumab intravenously plus MK-4830 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus MK-4830 plus lenvatinibLenvatinibParticipants will receive pembrolizumab intravenously plus MK-4830 plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus chemotherapyPembrolizumabParticipants will receive pembrolizumab intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Pembrolizumab plus MK-4830 plus ChemotherapyPembrolizumabParticipants will receive pembrolizumab intravenously plus MK-4830 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Primary Outcome Measures
NameTimeMethod
Number of Participants Experiencing a Dose-limiting Toxicity (DLT) During Safety Lead-in PhaseUp to approximately 3 weeks

A DLT is defined as any drug-related adverse event (AE) according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle.

Number of Participants Experiencing an Adverse Event (AE) During Safety Lead-in PhaseUp to approximately 3 Weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in PhaseUp to approximately 3 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Objective Response Rate (ORR)Up to approximately 40 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Secondary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS)Up to approximately 40 months

PFS is defined as the time from allocation to the first documented progressive disease (PD) as assessed by RECIST 1.1 or death due to any cause, whichever occurs first. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Duration of Response (DOR)Up to approximately 40 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

Overall Survival (OS)Up to approximately 40 months

OS is defined as the time from the date of allocation to death from any cause.

Number of Participants Experiencing at Least One Adverse Event (AE) During the Efficacy PhaseUp to approximately 40 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy PhaseUp to approximately 104 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Trial Locations

Locations (46)

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300)

🇧🇷

São Paulo, Sao Paulo, Brazil

Hopital Claude Huriez - CHU de Lille ( Site 1100)

🇫🇷

Lille, Nord, France

Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104)

🇫🇷

Brest, Finistere, France

Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 2801)

🇩🇪

Frankfurt, Hessen, Germany

Pitie Salpetriere University Hospital ( Site 1102)

🇫🇷

Paris, Orne, France

Universitaetsklinikum Duesseldorf ( Site 2802)

🇩🇪

Düsseldorf, Nordrhein-Westfalen, Germany

Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 2806)

🇩🇪

Dresden, Sachsen, Germany

Ospedale San Raffaele-Oncologia Medica ( Site 1206)

🇮🇹

Milano, Lombardia, Italy

Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 2804)

🇩🇪

Berlin, Germany

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1200)

🇮🇹

Milan, Lombardia, Italy

Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (

🇮🇹

Milano, Italy

Istituto Oncologico Veneto IRCCS ( Site 1205)

🇮🇹

Padova, Italy

Aichi Cancer Center Hospital ( Site 1702)

🇯🇵

Nagoya, Aichi, Japan

Saitama Prefectural Cancer Center ( Site 1703)

🇯🇵

Ina-machi, Saitama, Japan

Shizuoka Cancer Center ( Site 1704)

🇯🇵

Nagaizumi-cho,Sunto-gun, Shizuoka, Japan

Asan Medical Center-Department of Oncology ( Site 1901)

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center-Division of Hematology/Oncology ( Site 1900)

🇰🇷

Seoul, Korea, Republic of

Chang Gung Memorial Hospital at Kaohsiung ( Site 2003)

🇨🇳

Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan

Oslo universitetssykehus, Radiumhospitalet ( Site 2501)

🇳🇴

Oslo, Norway

Hôpitaux Universitaires de Genève (HUG) ( Site 2702)

🇨🇭

Genève, Geneve, Switzerland

National University Hospital ( Site 1800)

🇸🇬

Singapore, South West, Singapore

Kantonsspital Graubünden-Medizin ( Site 2700)

🇨🇭

Chur, Grisons, Switzerland

China Medical University Hospital ( Site 2007)

🇨🇳

Taichung, Taiwan

National Cheng Kung University Hospital ( Site 2001)

🇨🇳

Tainan, Taiwan

Taichung Veterans General Hospital-Radiation Oncology ( Site 2008)

🇨🇳

Taichung, Taiwan

National Taiwan University Hospital ( Site 2000)

🇨🇳

Taipei, Taiwan

Chang Gung Medical Foundation-Linkou Branch ( Site 2006)

🇨🇳

Taoyuan, Taiwan

Taipei Veterans General Hospital ( Site 2005)

🇨🇳

Taipei, Taiwan

Chulalongkorn University ( Site 2104)

🇹🇭

Bangkok, Krung Thep Maha Nakhon, Thailand

Faculty of Medicine Siriraj Hospital ( Site 2102)

🇹🇭

Bangkok, Krung Thep Maha Nakhon, Thailand

Acibadem Altunizade Hospital-Oncology ( Site 1407)

🇹🇷

Üsküdar / İstanbul, Istanbul, Turkey

Songklanagarind hospital ( Site 2105)

🇹🇭

Hatyai, Songkhla, Thailand

I.E.U. Medical Point Hastanesi-Oncology ( Site 1406)

🇹🇷

Izmir, Karsiyaka, Izmir, Turkey

Hacettepe Universite Hastaneleri-oncology hospital ( Site 1402)

🇹🇷

Ankara, Turkey

Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1417)

🇹🇷

Adana, Turkey

Memorial Ankara Hastanesi-Medical Oncology ( Site 1408)

🇹🇷

Ankara, Turkey

Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1410)

🇹🇷

Antalya, Turkey

Ankara City Hospital-Medical Oncology ( Site 1405)

🇹🇷

Ankara, Turkey

Atatürk Üniversitesi-onkoloji ( Site 1416)

🇹🇷

Erzurum, Turkey

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1403)

🇹🇷

Istanbul, Turkey

Hospital Nossa Senhora da Conceição ( Site 2301)

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Liga Norte Riograndense Contra o Câncer ( Site 2303)

🇧🇷

Natal, Rio Grande Do Norte, Brazil

National Cancer Center Hospital ( Site 1700)

🇯🇵

Chuo-ku, Tokyo, Japan

FALP-UIDO ( Site 2400)

🇨🇱

Santiago, Region M. De Santiago, Chile

Clínica las Condes ( Site 2403)

🇨🇱

Santiago, Region M. De Santiago, Chile

National Cancer Center Hospital East ( Site 1701)

🇯🇵

Kashiwa, Chiba, Japan

© Copyright 2025. All Rights Reserved by MedPath